- Home
- SNX vs EXEL Comparison
SNX vs EXEL Comparison
Compare SNX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- EXEL
- Stock Information
- Founded
- SNX 1980
- EXEL 1994
- Country
- SNX United States
- EXEL United States
- Employees
- SNX N/A
- EXEL N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNX Technology
- EXEL Health Care
- Exchange
- SNX Nasdaq
- EXEL Nasdaq
- Market Cap
- SNX 9.5B
- EXEL 9.4B
- IPO Year
- SNX 2003
- EXEL 2000
- Fundamental
- Price
- SNX $141.68
- EXEL $36.85
- Analyst Decision
- SNX Strong Buy
- EXEL Buy
- Analyst Count
- SNX 8
- EXEL 18
- Target Price
- SNX $144.38
- EXEL $37.24
- AVG Volume (30 Days)
- SNX 550.7K
- EXEL 2.5M
- Earning Date
- SNX 03-25-2025
- EXEL 02-11-2025
- Dividend Yield
- SNX 1.25%
- EXEL N/A
- EPS Growth
- SNX 18.72
- EXEL 170.77
- EPS
- SNX 7.95
- EXEL 1.76
- Revenue
- SNX $58,452,436,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- SNX $6.35
- EXEL $5.36
- Revenue Next Year
- SNX $5.39
- EXEL $10.59
- P/E Ratio
- SNX $17.73
- EXEL $20.87
- Revenue Growth
- SNX 1.56
- EXEL 18.49
- 52 Week Low
- SNX $101.21
- EXEL $20.14
- 52 Week High
- SNX $145.10
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- SNX 56.76
- EXEL 65.59
- Support Level
- SNX $140.26
- EXEL $34.01
- Resistance Level
- SNX $145.10
- EXEL $35.46
- Average True Range (ATR)
- SNX 2.09
- EXEL 1.09
- MACD
- SNX -0.72
- EXEL 0.36
- Stochastic Oscillator
- SNX 46.73
- EXEL 95.70
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and datacenter infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include, the Americas, Europe, and APJ.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.